An evaluation of the latest in vitro tools for drug metabolism studies

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 1, 2014, Pages 103-119

  Costa, Ana ^a   Sarmento, Bruno ^a,b   Seabra, Vítor ^a  

^a UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

^b INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

Author keywords

Hepatic metabolism; in vitro models; Intestinal metabolism; Pulmonary metabolism; Renal metabolism

Indexed keywords

ALGINIC ACID; DICLOFENAC; QUINIDINE; RIFAMPICIN;

BIOCHIP; CHEMICAL REACTION; DETOXIFICATION; DRUG ABSORPTION; DRUG APPROVAL; DRUG CLEARANCE; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY METABOLISM; LIVER METABOLISM; MICROFLUIDIC ANALYSIS; REVIEW; TOXIC HEPATITIS;

ANIMALS; CELL LINE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEPATOCYTES; HUMANS; INTESTINES; KIDNEY; LIVER; LUNG; METABOLIC DETOXICATION, DRUG; MODELS, THEORETICAL;

EID: 84890346695     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.857402     Document Type: Review

References (167)

1. Klaass C. Casarett and Doulls's toxicology: The basic science of poisons. In: Klaassen, CD, editors, 7th edition. McGraw-Hill, New York City, USA; 2008
2. Gad SC. Preclinical development handbook: Toxicology. John Wiley & Sons, Hoboken, New Jersey; 2008
3. Pieper I, Wechler K, Katzberg M, et al. Biosimulation of drug metabolism-A yeast based model. Eur J Pharm Sci 2009;36:157-70
4. Astashkina A, Mann B, Grainger DW. A critical evaluation of in vitro cell culture models for high-Throughput drug screening and toxicity. Pharmacol Ther 2012;134:82-106
5. Pelkonen O, Turpeinen M, Uusitalo J, et al. Prediction of drug metabolism and interactions on the basis of in vitro investigations. Basic Clin Pharmacol 2005;96:167-75
6. Venkatakrishnan K, von Moltke LL, Obach RS, Greenblatt DJ. Drug metabolism and drug interactions: Application and clinical value of in vitro models. Curr Drug Metab 2003;4:423-59
7. Wrighton SA, Ring BJ, Vandenbranden M. The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies. Toxicol Pathol 1995;23:199-208
8. De Kanter R, Olinga P, De Jager MH, et al. Organ slices as an in vitro test system for drug metabolism in human liver, lung and kidney. Toxicol In Vitro 1999;13:737-44
9. Vickers AEM, Fisher RL. Organ slices for the evaluation of human drug toxicity. Chem Biol Interact 2004;150:87-96
10. de Graaf IAM, Koster HJ. Cryopreservation of precision-cut tissue slices for application in drug metabolism research. Toxicol In Vitro 2003;17:1-17
11. Ekins S, Ring BJ, Grace J, et al. Present and future in vitro approaches for drug metabolism. J Pharmacol Toxicol 2000;44:313-24
12. Hariparsad N, Sane RS, Strom SC, Desai PB. In vitro methods in human drug biotransformation research: Implications for cancer chemotherapy. Toxicol in Vitro 2006;20:135-53
13. Langowski J, Long A. Computer systems for the prediction of xenobiotic metabolism. Adv Drug Deliv Rev 2002;54:407-15
14. Raunio H. In silico toxicology-nontesting methods. Front Pharmacol 2011;2:1-8
15. Kirchmair J, Williamson MJ, Tyzack JD, et al. Computational prediction of metabolism: Sites, products, SAR, P450 enzyme dynamics, and mechanisms. J Chem Inf Model 2012;52:617-48
16. Clewell RA, Clewell Iii HJ. Development and specification of physiologically based pharmacokinetic models for use in risk assessment. Regul Toxicol Pharmacol 2008;50:129-43
17. Jones HM, Gardner B, Watson KJ. Modelling and PBPK simulation in drug discovery. AAPS J 2009;11:155-66
18. Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol 2011;51:45-73
19. Chen Y, Jin JY, Mukadam S, et al. Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: Strategy and approach during the drug discovery phase with four case studies. Biopharm Drug Dispos 2012;33:85-98
20. Heikkinen AT, Baneyx G, Caruso A, Parrott N. Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates-An evaluation and case study using GastroPlus-. Eur J Pharm Sci 2012;47:375-86
21. Fan J, Chen S, Chow ECY, Pang KS. PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism. Curr Drug Metab 2010;11:743-61
22. Guillouzo A, Morel F, Fardel O, Meunier B. Use of human hepatocyte cultures for drug metabolism studies. Toxicology 1993;82:209-19
23. Cheng N, Wauthier E, Reid LM. Mature human hepatocytes from ex vivo differentiation of alginate-encapsulated hepatoblasts. Tissue Eng Part A 2008;14:1-7
24. Lu H-F, Chua K-N, Zhang P-C, et al. Three-dimensional co-culture of rat hepatocyte spheroids and NIH/3T3 fibroblasts enhances hepatocyte functional maintenance. Acta Biomater 2005;1:399-410
25. Abu-Absi SF, Friend JR, Hansen LK, Hu W-S. Structural polarity and functional bile canaliculi in rat hepatocyte spheroids. Exp Cell Res 2002;274:56-67
26. Chiang T-S, Yang K-C, Zheng S-K, et al. The prediction of drug metabolism using scaffold-mediated enhancement of the induced cytochrome P450 activities in fibroblasts by hepatic transcriptional regulators. Biomaterials 2012;33:5187-97
27. Gaedtke L, Thoenes L, Culmsee C, et al. Proteomic analysis reveals differences in protein expression in spheroid versus monolayer cultures of low-passage colon carcinoma cells. J Proteome Res 2007;6:4111-18
28. Toh Y-C, Lim TC, Tai D, et al. A microfluidic 3D hepatocyte chip for drug toxicity testing. Lab Chip 2009;9:2026-35
29. Sivaraman A, Leach JK, Townsend S, et al. A microscale in vitro physiological model of the liver: Predictive screens for drug metabolism and enzyme induction. Curr Drug Metab 2005;6:569-91
30. Leite SB, Teixeira AP, Miranda JP, et al. Merging bioreactor technology with 3D hepatocyte-fibroblast culturing approaches: Improved in vitro models for toxicological applications. Toxicol In Vitro 2011;25:825-32
31. Kostadinova R, Boess F, Applegate D, et al. A long-Term three dimensional liver co-culture system for improved prediction of clinically relevant druginduced hepatotoxicity. Toxicol Appl Pharmacol 2013;268:1-16
32. Lin R-Z, Chang H-Y. Recent advances in three-dimensional multicellular spheroid culture for biomedical research. Biotechnol J 2008;3:1172-84
33. Fennema E, Rivron N, Rouwkema J, et al. Spheroid culture as a tool for creating 3D complex tissues. Trends Biotechnol 2013;31:108-15
34. Miranda JP, Rodrigues A, Tostões RM, et al. Extending hepatocyte functionality for drug-Testing applications using highviscosity alginate-encapsulated threedimensional cultures in bioreactors. Tissue Eng Part C 2010;16:1223-32
35. Lan S-F, Starly B. Alginate based 3D hydrogels as an in vitro co-culture model platform for the toxicity screening of new chemical entities. Toxicol Appl Pharmacol 2011;256:62-72
36. Chia SM, Leong KW, Li J, et al. Hepatocyte encapsulation for enhanced cellular functions. Tissue Eng 2000;6:481-95
37. Schutte M, Fox B, Baradez MO, et al. Rat primary hepatocytes show enhanced performance and sensitivity to acetaminophen during three-dimensional culture on a polystyrene scaffold designed for routine use. Assay Drug Dev Technol 2011;9:475-86
38. Evenou F, Fujii T, Sakai Y. Liver cells culture on three-dimensional micropatterned polydimethylsiloxane surfaces. JSAAE 2007;14:665-8
39. Kaufmann PM, Heimrath S, Kim BS, Mooney DJ. Highly porous polymer matrices as a three-dimensional culture system for hepatocytes. Cell Transplant 1997;6:463-8
40. Wang C, Varshney RR, Wang D-A. Therapeutic cell delivery and fate control in hydrogels and hydrogel hybrids. Adv Drug Deliv Rev 2010;62:699-710
41. Lee KY, Mooney DJ. Alginate: Properties and biomedical applications. Prog Polym Sci 2012;37:106-26
42. Meli L, Jordan ET, Clark DS, et al. Influence of a three-dimensional, microarray environment on human Cell culture in drug screening systems. Biomaterials 2012;33:9087-96
43. Nakamura K, Mizutani R, Sanbe A, et al. Evaluation of drug toxicity with hepatocytes cultured in a micro-space cell culture system. J Biosci Bioeng 2011;111:78-84
44. Gurski LA, Jha AK, Zhang C, et al. Hyaluronic acid-based hydrogels as 3D matrices for in vitro evaluation of chemotherapeutic drugs using poorly adherent prostate cancer cells. Biomaterials 2009;30:6076-85
45. Horning JL, Sahoo SK, Vijayaraghavalu S, et al. 3-D tumor model for in vitro evaluation of anticancer drugs. Mol Pharm 2008;5:849-62
46. David L, Dulong V, Le Cerf D, et al. Hyaluronan hydrogel: An appropriate three-dimensional model for evaluation of anticancer drug sensitivity. Acta Biomater 2008;4:256-63
47. Lan S-F, Safiejko-Mroczka B, Starly B. Long-Term cultivation of HepG2 liver cells encapsulated in alginate hydrogels: A study of cell viability, morphology and drug metabolism. Toxicol In Vitro 2010;24:1314-23
48. Naughton B, Sibanda B, Weintraub J, et al. A stereotypic, transplantable liver tissue-culture system. Appl Biochem Biotechnol 1995;54:65-91
49. Dash A, Inman W, Hoffmaster K, et al. Liver tissue engineering in the evaluation of drug safety. Expert Opin Drug Metab Toxicol 2009;5:1159-74
50. Khetani SR, Bhatia SN. Microscale culture of human liver cells for drug development. Nat Biotechnol 2008;26:120-6
51. Kuri-Harcuch W, Mendoza-Figueroa T. Cultivation of adult rat hepatocytes on 3T3 cells: Expression of various liver differentiated functions. Differentiation 1989;41:148-57
52. Uyama N, Shimahara Y, Kawada N, et al. Regulation of cultured rat hepatocyte proliferation by stellate cells. J Hepatol 2002;36:590-9
53. Zinchenko YS, Culberson CR, Coger RN. Contribution of nonparenchymal cells to the performance of micropatterned hepatocytes. Tissue Eng 2006;12:2241-1251
54. Bhandari R, Riccalton L, Lewis A, et al. Liver tissue engineering: A role for coculture systems in modifying hepatocyte function and viability. Tissue Eng 2001;7:345-57
55. Bhatia SN, Balis UJ, Yarmush ML, Toner M. Effect of cell-cell interactions in preservation of cellular phenotype: Cocultivation of hepatocytes and nonparenchymal cells. FASEB J 1999;13:1883-900
56. Kidambi S, Sheng L, Yarmush ML, et al. Patterned co-culture of primary hepatocytes and fibroblasts using polyelectrolyte multilayer templates. Macromol Biosci 2007;7:344-53
57. Gerlach J. Use of hepatocyte cultures for liver support bioreactors. In: Felipo V, Grisolia S, editors. Hepatic encephalopathy, hyperammonemia, and ammonia toxicity. Springer; US: 1994. p. 165-71
58. Varley J, Birch J. Reactor design for large scale suspension animal cell culture. Cytotechnology 1999;29:177-205
59. Tostões RM, Leite SB, Serra M, et al. Human liver cell spheroids in extended perfusion bioreactor culture for repeateddose drug testing. Hepatology 2012;55:1227-36
60. Tostões RM, Leite SB, Miranda JP, et al. Perfusion of 3D encapsulated hepatocytes-A synergistic effect enhancing long-Term functionality in bioreactors. Biotechnol Bioeng 2011;108:41-9
61. Guzzardi MA, Vozzi F, Ahluwalia AD. Study of the crosstalk between hepatocytes and endothelial cells using a novel multicompartmental bioreactor: A comparison between connected cultures and cocultures. Tissue Eng Part A 2009;15:3635-44
62. Mazzoleni G, Steimberg N. New models for the in vitro study of liver toxicity: 3D culture systems and the role of bioreactors. In: Tyshenko M, editor. The continuum of health risk assessments. InTech; Hampshire, UK: 2012. p. 161-94
63. De Bruyn T, Chatterjee S, Fattah S, et al. Sandwich-cultured hepatocytes: Utility for in vitro exploration of hepatobiliary drug disposition and druginduced hepatotoxicity. Expert Opin Drug Metab Toxicol 2013;9:589-616
64. LeCluyse EL. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 2001;13:343-68
65. Ghibellini G, Vasist LS, Leslie EM, et al. In vitro-in vivo correlation of hepatobiliary drug clearance in humans. Clin Pharmacol Ther 2007;81:406-13
66. Boess F, Kamber M, Romer S, et al. Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: Possible implications for toxicogenomics use of in vitro systems. Toxicol Sci 2003;73:386-402
67. Tuschl G, Hrach J, Walter Y, et al. Serum-free collagen sandwich cultures of adult rat hepatocytes maintain liver-like properties long term: A valuable model for in vitro toxicity and drug-drug interaction studies. Chem Biol Interact 2009;181:124-37
68. Tchaparian EH, Houghton JS, Uyeda C, et al. Effect of culture time on the basal expression levels of drug transporters in sandwich-cultured primary rat hepatocytes. Drug Metab Dispos 2011;39:2387-94
69. Soldatow VY, LeCluyse EL, Griffith LG, Rusyn I. In vitro models for liver toxicity testing. Toxicol Res 2013;2:23-9
70. Kimoto E, Walsky R, Zhang H, et al. Differential modulation of cytochrome P450 activity and the effect of 1-Aminobenzotriazole on hepatic transport in sandwich-cultured human hepatocytes. Drug Metab Dispos 2012;40:407-11
71. Muller M, Jansen PL. Molecular aspects of hepatobiliary transport. Am J Physiol 1997;272:1285-303
72. Sai Y. Biochemical and molecular pharmacological aspects of transporters as determinants of drug disposition. Drug Metab Pharmacokinet 2005;20:91-9
73. Morgan RE, Trauner M, van Staden CJ, et al. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci 2010;118:485-500
74. Borlak J, Klutcka T. Expression of basolateral and canalicular transporters in rat liver and cultures of primary hepatocytes. Xenobiotica 2004;34:935-47
75. Kotani N, Maeda K, Watanabe T, et al. Culture period-dependent changes in the uptake of transporter substrates in sandwich-cultured rat and human hepatocytes. Drug Metab Dispos 2011;39:1503-10
76. Jacobsen JK, Jensen B, Skonberg C, et al. Time-course activities of Oct1, Mrp3, and cytochrome P450s in cultures of cryopreserved rat hepatocytes. Eur J Pharm Sci 2011;44:427-36
77. Jørgensen L, Van Beek J, Lund S, et al. Evidence of Oatp and Mdr1 in cryopreserved rat hepatocytes. Eur J Pharm Sci 2007;30:181-9
78. Li N, Singh P, Mandrell KM, Lai Y. Improved extrapolation of hepatobiliary clearance from in vitro sandwich cultured rat hepatocytes through absolute quantification of hepatobiliary transporters. Mol Pharm 2010;7:630-41
79. Hoffmaster K, Turncliff R, LeCluyse E, et al. P-glycoprotein expression, localization, and function in sandwichcultured primary rat and human hepatocytes: Relevance to the hepatobiliary disposition of a model opioid peptide. Pharm Res 2004;21:1294-302
80. Takayama K, Inamura M, Kawabata K, et al. Generation of metabolically functioning hepatocytes from human pluripotent stem cells by FOXA2 and HNF1alpha transduction. J Hepatol 2012;57:628-36
81. Hay DC, Zhao D, Ross A, et al. Direct differentiation of human embryonic stem cells to hepatocyte-like cells exhibiting functional activities. Cloning Stem Cells 2007;9:51-62
82. Hay DC, Zhao D, Fletcher J, et al. Efficient differentiation of hepatocytes from human embryonic stem cells exhibiting markers recapitulating liver development in vivo. Stem Cells 2008;26:894-902
83. Agarwal S, Holton KL, Lanza R. Efficient differentiation of functional hepatocytes from human embryonic stem cells. Stem Cells 2008;26:1117-27
84. Hay DC, Fletcher J, Payne C, et al. Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling. Proc Natl Acad Sci USA 2008;105:12301-6
85. Duan Y, Ma X, Zou W, et al. Differentiation and characterization of metabolically functioning hepatocytes from human embryonic stem cells. Stem Cells 2010;28:674-86
86. Song Z, Cai J, Liu Y, et al. Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells. Cell Res 2009;19:1233-42
87. Yi F, Liu G-H, Belmonte J. Human induced pluripotent stem cells derived hepatocytes: Rising promise for disease modeling, drug development and cell therapy. Protein Cell 2012;3:246-50
88. Alison MR, Poulsom R, Jeffery R, et al. Cell differentiation: Hepatocytes from non-hepatic adult stem cells. Nature 2000;406:257-7
89. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418:41-9
90. Scarpelli DG, Rao MS. Differentiation of regenerating pancreatic cells into hepatocyte-like cells. Proc Natl Acad Sci USA 1981;78:2577-81
91. Yu Y, Liu H, Ikeda Y, et al. Hepatocyte-like cells differentiated from human induced pluripotent stem cells: Relevance to cellular therapies. Stem Cell Res 2012;9:196-207
92. Graaf IA, Groothuis GM, Olinga P. Precision-cut tissue slices as a tool to predict metabolism of novel drugs Expert Opin Drug Metab Toxicol 2007;3:879-98
93. van Midwoud PM, Merema MT, Verpoorte E, Groothuis GMM. A microfluidic approach for in vitro assessment of interorgan interactions in drug metabolism using intestinal and liver slices. Lab Chip 2010;10:2778-86
94. Van Midwoud PM, Merema MT, Verweij N, et al. Hydrogel embedding of precision-cut liver slices in a microfluidic device improves drug metabolic activity. Biotechnol Bioeng 2011;108:1404-12
95. Khong Y, Zhang J, Zhou S, et al. Novel intra-Tissue perfusion system for culturing thick liver tissue. Tissue Eng 2007;13:2345-56
96. Schumacher K, Khong Y, Chang S, et al. Perfusion culture improves the maintenance of cultured liver tissue slices. Tissue Eng 2007;13:197-205
97. van Midwoud PM, Merema MT, Verpoorte E, Groothuis GMM. Microfluidics enables small-scale tissuebased drug metabolism studies with scarce human tissue. J Assoc Lab Autom 2011;16:468-76
98. Ganey PE, Luyendyk JP, Maddox JF, Roth RA. Adverse hepatic drug reactions: Inflammatory episodes as consequence and contributor. Chem Biol Interact 2004;150:35-51
99. Adams DH, Ju C, Ramaiah SK, et al. Mechanisms of immune-mediated liver injury. Toxicol Sci 2010;115:307-21
100. Uetrecht J. Idiosyncratic drug reactions: Past, present, and future. Chem Res Toxicol 2007;21:84-92
101. Shaw PJ, Ganey PE, Roth RA. Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol Sci 2010;118:7-18
102. Uetrecht J. Idiosyncratic drug reactions: Current understanding. Annu Rev Pharmacol 2007;47:513-39
103. Hadi M, Chen Y, Starokozhko V, et al. Mouse precision-cut liver slices as an ex vivo model to study idiosyncratic drug-induced liver injury. Chem Res Toxicol 2012;25:1938-47
104. Hadi M, Westra IM, Starokozhko V, et al. Human precision-cut liver slices as an ex vivo model to study idiosyncratic drug-induced liver injury. Chem Res Toxicol 2013;26:710-20
105. Obach R. Predicting clearance in humans from in vitro data. Curr Top Med Chem 2011;11:334-9
106. Riley RJ, McGinnity DF, Austin RP. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microssomes. Drug Metab Dispos 2005;33:1304-11
107. Blanchard N, Hewitt N, Silber P, et al. Prediction of hepatic clearance using cryopreserved human hepatocytes: A comparison of serum and serum-free incubations. J Pharm Pharmacol 2006;58:633-41
108. Poulin P, Hop CECA, Ho Q, et al. Comparative assessment of in vitro-in vivo extrapolation methods used for predicting hepatic metabolic clearance of drugs. J Pharm Sci 2012;101:4308-26
109. Chiba M, Ishii Y, Sugiyama Y. Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J 2009;11:262-76
110. Houston J, Carlile D. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev 1997;29:891-22
111. Li AP. Human hepatocytes: Isolation, cryopreservation and applications in drug development. Chem Biol Interact 2007;168:16-29
112. Hallifax D, Rawden HC, Hakooz N, Houston JB. Prediction of metabolic clearance using cryopreserved human hepatocytes: Kinetics characteristics for five benzodiazepines. Drug Metab Dispos 2005;33:1852-8
113. Poulin P. Prediction of total hepatic clearance by combining metabolism, transport, and permeability data in the in vitro-in vivo extrapolation methods: Emphasis on an apparent fraction unbound in liver for drugs. J Pharm Sci 2013;102:2085-95
114. Umehara KI, Camenisch G. Novel in vitro-in vivo extrapolation (IVIVE) method to predict hepatic organ clearance in rat. Pharm Res 2012;29:603-17
115. von Richter O, Burk O, Fromm MF, et al. Cytochrome P450 3A4 and Pglycoprotein expression in human small intestinal enterocytes and hepatocytes: A comparative analysis in paired tissue specimens [abstract]. Clin Pharmacol Ther 2004;75:172-83
116. Krishna D, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 1994;26:144-60
117. Takemoto K, Yamazaki H, Tanaka Y, et al. Catalytic activities of cytochrome P450 enzymes and UDPglucuronosyltransferases involved in drug metabolism in rat everted sacs and intestinal microsomes. Xenobiotica 2003;33:43-55
118. Thorn M, Finnstrom N, Lundgren S, et al. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 2005;60:54-60
119. Wacher VJ, Salphati L, Benet LZ. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 2001;46:89-102
120. Kolars JC, Schmiedlin-Ren P, Schuetz JD, et al. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-8
121. Deferme S, Annaert P, Augustijns P. In vitro screening models to assess intestinal drug absorption and metabolism. In: Ehrhardt C, Kim K-J, editors. Drug absorption studies. Springer; US: 2008. p. 182-215
122. Murakami T, Takano M. Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol 2008;4:923-39
123. Yokooji T, Yumoto R, Nagai J, et al. Role of intestinal efflux transporters in the intestinal absorption of methotrexate in rats. J Pharm Pharmacol 2007;59:1263-70
124. Mouly S, Paine M. P-Glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 2003;20:1595-9
125. Meier Y, Eloranta JJ, Darimont J, et al. Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab Dispos 2007;35:590-4
126. Englund G, Rorsman F, Ronnblom A, et al. Regional levels of drug transporters along the human intestinal tract: Coexpression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci 2006;29:269-77
127. Hu M, Ling J, Lin H, Chen J. Use of Caco-2 cell monolayers to study drug absorption and metabolism. In: Yan Z, Caldwell G, editors. Methods in pharmacology and toxicology optimization in drug discovery: In vitro methods. Humana Press; Totowa, New Jersey: 2004. p. 19-35
128. Carrière V, Chambaz J, Rousset M. Intestinal responses to xenobiotics. Toxicol in Vitro 2001;15:373-8
129. Borlak J, Zwadlo C. Expression of drugmetabolizing enzymes, nuclear transcription factors and ABC transporters in Caco-2 cells. Xenobiotica 2003;33:927-43
130. Taipalensuu J, Tornblom H, Lindberg G, et al. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 2001;299:164-70
131. Maubon N, Le Vee M, Fossati L, et al. Analysis of drug transporter expression in human intestinal Caco-2 cells by realtime PCR. Fundam Clin Pharmacol 2007;21:659-63
132. Sambuy Y, Angelis I, Ranaldi G, et al. The Caco-2 cell line as a model of the intestinal barrier: Influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol Toxicol 2005;21:1-26
133. Siissalo S, Heikkinen AT. In vitro methods to study the interplay of drug metabolism and efflux in the intestine. Curr Drug Metab 2013;14:102-11
134. van de Kerkhof EG, Ungell A-LB, Sjoberg A K, et al. Innovative methods to study human intestinal drug metabolism in vitro: Precision-cut slices compared with ussing chamber preparations. Drug Metab Dispos 2006;34:1893-902
135. Groothuis G, de Graaf I. Precision-cut intestinal slices as in vitro tool for studies on drug metabolism. Curr Drug Metab 2013;14:112-19
136. Yu J, Peng S, Luo D, March JC. In vitro 3D human small intestinal villous model for drug permeability determination. Biotechnol Bioeng 2012;109:2173-8
137. Li N, Wang D, Sui Z, et al. Development of an improved threedimensional in vitro intestinal mucosa model for drug absorption evaluation. Tissue Eng Part C Methods 2013;19:1-12
138. Antunes F, Andrade F, Araujo F, et al. Establishment of a triple co-culture in vitro cell models to study intestinal absorption of peptide drugs. Eur J Pharm Biopharm 2013;83:427-35
139. Hukkanen J, Pelkonen O, Hakkola J, Raunio H. Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit Rev Toxicol 2002;32:391-411
140. Castell JV, Teresa Donato M, Gómez-Lechón MJ. Metabolism and bioactivation of toxicants in the lung. The in vitro cellular approach. Exp Toxicol Pathol 2005;57:189-204
141. Foster KA, Oster CG, Mayer MM, et al. Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism. Exp Cell Res 1998;243:359-66
142. Newland N, Baxter A, Hewitt K, Minet E. CYP1A1/1B1 and CYP2A6/ 2A13 activity is conserved in cultures of differentiated primary human tracheobronchial epithelial cells. Toxicol in Vitro 2011;25:922-9
143. Foster KA, Avery ML, Yazdanian M, Audus KL. Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery. Int J Pharm 2000;208:1-11
144. Forbes B, Ehrhardt C. Human respiratory epithelial cell culture for drug delivery applications. Eur J Pharm Biopharm 2005;60:193-205
145. Florea BI, Cassara ML, Junginger HE, Borchard G. Drug transport and metabolism characteristics of the human airway epithelial cell line Calu-3. J Control Release 2003;87:131-8
146. Forbes B. Human airway epithelial cell lines for in vitro drug transport and metabolism studies. Pharm Sci Technol Today 2000;3:18-27
147. Ehrhardt C, Kneuer C, Fiegel J, et al. Influence of apical fluid volume on the development of functional intercellular junctions in the human epithelial cell line 16HBE14o-: Implications for the use of this cell line as an in vitro model for bronchial drug absorption studies. Cell Tissue Res 2002;308:391-400
148. Proud D, Subauste MC, Ward PE. Glucocorticoids do not alter peptidase expression on a human bronchial epithelial cell line. Am J Respir Cell Mol Biol 1994;11:57-65
149. Eaton E, Walle U, Wilson H, et al. Stereoselective sulphate conjugation of salbutamol by human lung and bronchial epithelial cells. Br J Clin Pharmacol 1996;41:201-6
150. Garcia-Canton C, Minet E, Anadon A, Meredith C. Metabolic characterization of cell systems used in in vitro toxicology testing: Lung cell system BEAS-2B as a working example. Toxicol In Vitro published online 10 May 2013; doi:10.1016/j.tiv.2013.05.001
151. Persoz C, Achard S, Momas I, Seta N. Inflammatory response modulation of airway epithelial cells exposed to formaldehyde. Toxicol Lett 2012;211:159-63
152. Veljkovic E, Jiricny J, Menigatti M, et al. Chronic exposure to cigarette smoke condensate in vitro induces epithelial to mesenchymal transition-like changes in human bronchial epithelial cells, BEAS-2B. Toxicol In Vitro 2011;25:446-53
153. Haniu H, Saito N, Matsuda Y, et al. Effect of dispersants of multi-walled carbon nanotubes on cellular uptake and biological responses. Int J Nanomed 2011;6:3295-307
154. Courcot E, Leclerc J, Lafitte J-J, et al. Xenobiotic metabolism and disposition in human lung cell models: Comparison with in vivo expression profiles. Drug Metab Dispos 2012;40:1953-65
155. Lehmann AD, Daum N, Bur M, et al. An in vitro triple cell co-culture model with primary cells mimicking the human alveolar epithelial barrier. Eur J Pharm Biopharm 2011;77:398-406
156. Lohr JW, Willsky GR, Acara MA. Renal drug metabolism. Pharmacol Rev 1998;50:107-42
157. Murray GI, McFadyen MCE, Mitchell RT, et al. Cytochrome P450 CYP3A in human renal cell cancer. Br J Cancer 1999;79:1836-42
158. Haehner BD, Gorski JC, Vandenbranden M, et al. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 1996;50:52-9
159. Loaiza-PÉRez AI, Kenney S, Boswell J, et al. Sensitivity of renal cell carcinoma to aminoflavone: Role of CYP 1A1. J Urol 2004;171:1688-97
160. Vrignaud P, Sémiond D, Lejeune P, et al. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin Cancer Res 2013;19:2973-83
161. Glube N, Giessl A, Wolfrum U, Langguth P. Caki-1 cells represent an in vitro model system for studying the human proximal tubule epithelium. Nephron Exp Nephrol 2007;107:47-56
162. Mullin JM, Cha CJ, Kleinzeller A. Metabolism of L-lactate by LLC-PK1 renal epithelia. Am J Physiol 1982;242:41-5
163. Baudoin R, Griscom L, Monge M, et al. Development of a renal microchip for in vitro distal tubule models. Biotechnol Prog 2007;23:1245-53
164. Choucha-Snouber L, Griscom L, Poleni P, et al. Liver-kidney microfluid bioreactor for cell co-culture in drug studies. 14th International Conference on Miniaturized Systems for Chemistry and Life Sciences; 2010. p. 833-5
165. Subramanian B, Rudym D, Cannizzaro C, et al. Tissue-engineered three-dimensional in vitro models for normal and diseased kidney. Tissue Eng Part A 2010;16:2821-31
166. Xu J, Patton D, Jackson SK, Purcell WM. In-vitro maintenance and functionality of primary renal tubules and their application in the study of relative renal toxicity of nephrotoxic drugs. J Pharmacol Toxicol Methods 2013;68:269-74
167. Enomoto A, Niwa T. Roles of organic anion transporters in the progression of chronic renal failure. Ther Apher Dial 2007;11:27-31